SCHEMBL2169948

SCHEMBL2169948

CC1(C)C(=O)N(C2C3CC4CC(C3)CC2C4)N1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
POLB P06746 2/20 0.44
LMNA P02545 2/20 0.41
HSD11B1 P28845 1/20 0.40
ATM Q13315 1/20 0.40
HTT P42858 2/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MMP2 P08253 1/20 0.38
PSEN1 P49768 3/20 0.38
PSEN2 P49810 3/20 0.38
APH1B Q8WW43 3/20 0.38
NCSTN Q92542 3/20 0.38
APH1A Q96BI3 3/20 0.38
PSENEN Q9NZ42 3/20 0.38
ACHE P22303 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170125 0.87 SMN1; SMN2 (0.37) KMT2AMEN1POLBHSD11B1TSHR
SCHEMBL2170303 0.86 MEN1 (0.44) KMT2AMEN1POLBHSD11B1MMP2
SCHEMBL2170001 0.81 FAAH (0.40) KMT2AHSD11B1
SCHEMBL2169997 0.78 CTSG (0.40) POLBLMNAHSD11B1TSHRALDH1A1
SCHEMBL2168749 0.76 ELANE (0.41) KMT2AMEN1HSD11B1TSHRALDH1A1
SCHEMBL2168942 0.76 NPSR1 (0.42) KMT2AMEN1HSD11B1NPSR1L3MBTL1
SCHEMBL2169858 0.75 MMP2 (0.48) KMT2AMEN1POLBLMNAHSD11B1
SCHEMBL2170264 0.74 CXCR3 (0.40) LMNAHSD11B1HTTALOX12NPSR1
SCHEMBL2169179 0.72 KMT2A (0.39) KMT2AMEN1POLBATML3MBTL1
SCHEMBL2169487 0.70 PDCD1 (0.40) KMT2AMEN1ALOX12MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 KMT2A 3619/4885MEN1 490/4885POLB 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.